BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
BioXcel Therapeutics(BTAI) Newsfilter·2024-04-24 22:30BioXcel Therapeutics, Inc. - BioXcel Therapeutics, Inc.（NASDAQ：BTAI）是一家利用人工智能开发神经科学和免疫肿瘤学转化药物的生物制药公司[5] - BXCL701是一种正在研究中的口服先天免疫激活剂，旨在在肿瘤微环境中引发炎症[4] - BXCL701被评定为孤儿药品，用于治疗急性髓细胞白血病、胰腺癌、Ⅱb至Ⅳ期黑色素瘤和软组织肉瘤[4]